Stroke and TIA Evaluations in Neurologically Underserved Regions Ganesh Asaithambi, MD John Nasseff Neuroscience Specialty Clinic 11/8/18.

Slides:



Advertisements
Similar presentations
Antiplatelet and anticoagulant therapy in stroke prevention
Advertisements

TPA… SMART or not SMART? That is the Question. Sarah Parker, MD.
What is a Stroke? Lumen ventricle A stroke is an injury to the brain caused by interruption of its blood flow, or by bleeding into or around the brain.
STROKESTROKESTROKESTROKE. Why Change? Improve Mortality Improve Mortality Devastating and Life Altering Devastating and Life Altering Cost expense of.
Copyright © 2008 Delmar Learning. All rights reserved. Unit 43 Nervous System.
SPECT imaging in cerebrovascular disease Measurement of regional cerebral blood flow (rCBF) Sensitive indicator of perfusion Diagnosis and prognosis of.
Canadian Cardiovascular Society Antiplatelet Guidelines
Andrew W. Asimos, MD, FACEP Transient Ischemic Attack Patient Update: The Optimal Management of Emergency Department Patients With Suspected Cerebral Ischemia.
Atrial Fibrillation in Patients with Cryptogenic Stroke Gladstone DJ et al. N Engl J Med 2014; 370: Presented by Kris Huston | July 21, 2014.
Stroke Issues & prevention. Agenda  Impact of Stroke –Definitions –Epidemiology –Risk factors  Management of Stroke –Acute management –Primary & Secondary.
Anticoagulation in Acute Ischemic Stroke. TPA: Tissue Plasminogen Activator 1995: NINDS study of TPA administration Design: randomized, double blind placebo-controlled.
STROKE Dr Ubaid N P Community Medicine Pariyaram Medical College.
ESUS: Embolic Strokes of Undetermined Source
Cerebral Vascular Disease
Stroke 101 Goals of Presentation What is a stroke? Types of stroke Warning signs of stroke Why did I have a stroke? Are there treatments for stroke?
FERNE/EMRA The Management of ED TIA Patients: What is the optimal outpatient work-up, treatment and disposition?
Edward P. Sloan, MD, MPH, FACEP EMRA /FERNE Case Conference: The ED Management of TIA, AIS and ICH Patients.
Transient Ischemic Attack (TIA): The Calm Before the Storm
Transthoracic Echocardiography in Cerebrovascular Disease Nisha I Parikh, MD MPH Noninvasive Imaging Conference May 14 th 2008.
Cardiovascular Diseases Why should you establish and maintain healthful habits to care for your heart?
Consultant Neurologist,
SIGN CHD In Scotland in the year ending 31 March 2006 over 10,300 patients died from CHD and 5,800 from cerebrovascular disease, with.
Secondary prevention after a TIA or ischemic stroke.
ACTIVE Clopidogrel plus Aspirin versus Aspirin in Patients Unsuitable for Warfarin.
Andrew W. Asimos, MD, FACEP Transient Ischemic Attack Patient Update: The Optimal Management of Emergency Department Patients With Suspected Cerebral Ischemia.
Acute Stroke: Principles of Modern Management A program of the American Academy of Neurology The AAN Acute Stroke Management courses are supported in part.
 Topic: Stroke- Cerebrovascular Disease Presented by: Adeela Hussain Presented to: Dr. Leslye Johnson.
Stroke Damrongsak Bulyalert, M.D., Ph.D.
Treatment of Ischaemic Stroke The American Heart Association American Stroke Association Guidelines Stroke. 2007;38:
Update in ESC: Dabigatran among OAC
Clinical Overview Director, Stanford Stroke Center Stanford University Palo Alto, California Gregory W. Albers, MD.
Chapter 6 Cerebrovascular Disease and Stroke. Stroke: Loss or impairment of body function resulting from injury or death of brain cells following insufficient.
Cerebrovascular diseases
Ask for a smile Ask for a stretch The sky is blue in Boston Ask for a sentence BRAIN ATTACK - STROKE By: Saleem Ahmed Sangi ( )
Dr. Meg-angela Christi M. Amores
Cerebrovascular Disease Nicholas Cascone, PA-C. Stroke – general characteristics  3 rd most common cause of death in US  Higher incidence in men, blacks,
Rikki Weems, PGY III August 20, 2015
©2013 Delmar, Cengage Learning. All Rights Reserved. May not be scanned, copied, duplicated, or posted to a publicly accessible website, in whole or in.
Cardioembolic Stroke: Diagnosis and Management
Antithrombotic and Thrombolytic Therapy for Ischemic Stroke Antithrombotic Therapy and Prevention of Thrombosis: ACCP Evidence-Based Clinical Practice.
Why Treat Patent Forman Ovale Clifford J Kavinsky, MD, PHD Professor of Medicine and pediatrics Associate Director, Center for Congenital and Structural.
Antithrombotic and Thrombolytic Therapy for Ischemic Stroke Antithrombotic Therapy and Prevention of Thrombosis: ACCP Evidence-Based Clinical Practice.
ACUTE STROKE Alexa Lauch IMG 310 Summer Semester 2016.
ESUS in the Athens Stroke Registry George Ntaios University of Thessaly, Larissa/Greece Barcelona, 08 June 2016.
Stroke By Asma Khatoon (Rph) Hospital Pharmacist at Ziauddin Hospital, Karachi.
Don’t Be Numb to the Signs of a Stroke Julia Thomas, PT Director of Therapy Services.
1 R1 임준욱 Anticoagulant and Antiplatelet Therapy Use in 426 Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention and Stent Implantation.
IN THE NAME OF GOD Dr. h-kayalha Anesthesiologist.
Management of Acute ISCHEMIC stroke
Stroke Condition characterized by rapidly developing signs and symptoms of a focal brain lesion with symptoms lasting for more than 24hrs with no apparent.
Cardiovascular Disease Project: Stroke
Cryptogenic Stroke and AF
Advances in Treatment for Acute Stroke
Cerebral Vascular Accident
A Comparison of RE-LY and ROCKET AF Trial Designs and Outcomes
Cerebrovascular Disorders
Quality of Referrals Guideline Congruence of referrals to TIAMS clinic
Stroke Niazy B Hussam.
ACTIVE A Effects of Addition of Clopidogrel to Aspirin in Patients with Atrial Fibrillation who are Unsuitable for Vitamin K Antagonists.
A. Epidemiology update:
Strokes.
Fibrillazione atriale
Patient Education Public education must involve all age groups. Incorporating stroke into basic life support (BLS) and cardiopulmonary resuscitation (CPR)
TIA/Stroke (1) C.L.I.P.S. Why do we care?
Stroke 101.
Cerebrovascular disease
Stroke: The Brain Attack
Simvastatin in Patients With Prior Cerebrovascular Disease: HPS
STROKE AWARENESS MONTH
Presentation transcript:

Stroke and TIA Evaluations in Neurologically Underserved Regions Ganesh Asaithambi, MD John Nasseff Neuroscience Specialty Clinic 11/8/18

Disclosures No relevant financial or competing interests

Objectives Discuss current burden of stroke and TIA Review acute evaluations for patients presenting with acute stroke symptoms Identify methods of evaluation for stroke and TIA patients for secondary prevention

What is a stroke?

What is a transient ischemic attack (TIA)?

Background 795,000 people in US have a stroke each year A stroke occurs every 40 seconds in the US Every 4 minutes a stroke-related death occurs Women between ages of 45-54 are twice as likely to have and die from a stroke than breast cancer Fifth leading cause of death in US Leading cause of disability Benjamin EJ et al. Circulation 2018;137:e67-e492.

The Basics: Types of Stroke APPROVED:STROKE PROMO DECK Hemorrhagic Stroke (13%) Ischemic Stroke (87%) Large Vessel Disease Intracerebral Hemorrhage Cryptogenic Cardioembolism Subarachnoid Hemorrhage Cerebrovascular disease is a heterogeneous disease. A stroke occurs when a blood vessel that supplies oxygen and nutrients to the brain becomes blocked or ruptures. A portion of the brain dependent on blood flow from this vessel becomes deprived of oxygen. Within minutes, nerve cells begin to die, which results in permanent disability. Strokes can be categorized as either hemorrhagic or ischemic.1 Hemorrhagic strokes occur as a result of bleeding into the brain caused by an injury to the head or a ruptured aneurysm. Although less common than ischemic strokes, hemorrhagic strokes produce more fatalities. Hemorrhagic strokes are further categorized as intracerebral or subarachnoid. An intracerebral hemorrhage occurs when a defective artery in the brain ruptures and the surrounding area of the brain fills with blood. A subarachnoid hemorrhage occurs when a blood vessel on the surface of the brain ruptures and bleeds into the subarachnoid space between the skull (but not within the tissues of the brain). Ischemic strokes can be further divided into subcategories. A cerebral embolism is a result of a clot or embolus that forms in another portion of the body such as the heart (in the case of atrial fibrillation) and is carried through the bloodstream, becomes lodged in an artery that supplies blood to the brain, and blocks the flow of blood. Atherosclerotic cerebrovascular disease results in stroke when there is an impediment to normal blood perfusion as a result of severe arterial stenosis or occlusion due to atherosclerosis and coexisting thrombosis.2 Lacunar infarcts result from microatheroma, lipohyalinosis, and other occlusive diseases of the small penetrating arteries of the brain; these are sometimes referred to as subcortical infarcts. Cryptogenic infarcts refer to ischemic strokes in which the underlying etiology remains obscure. Of the definite or probable strokes reported in the National Heart, Lung, and Blood Institute’s (NHLBI’s) Atherosclerosis Risk In Communities (ARIC) study,3 83% were ischemic, 10% were intracerebral, and 7% were subarachnoid hemorrhages. Among the 178 confirmed thrombotic brain infarctions, 38% were classified as lacunar strokes, occurring in small blood vessels of the brain. Small vessel disease Benjamin EJ et al. Circulation 2018;137:e67-e492. References American Stroke Association. Impact of Stroke. Available at: www.strokeassociation.org. Accessed June 21, 2002. Albers GW, Easton JD, Sacco RL. Antithrombotic and thrombolytic therapy for ischemic stroke. Chest. 1998;114:683S-698S. Rosamond WD, Folsom AR, Chambless LE, et al. Stroke incidence and survival among middle-aged adults: 9-year follow-up of the Atherosclerosis Risk In Communities (ARIC) cohort. Stroke. 1999;30:736-743.

Stroke in Minnesota (2016) ~2.5% of adults in Minnesota reported ever having had a stroke in their lifetime More than 100,000 people More than 5% of all deaths in Minnesota are due to stroke (2,197 deaths in 2016) Fifth-leading cause of death in the state More than 11,000 hospitalizations for acute stroke events Ranked 11th lowest for overall stroke mortality among states and District of Columbia From 2010-2016, stroke death rate is 26% higher in African-Americans and Asians compared to whites Minnesota Department of Health

System of Stroke Care in Minnesota As July 1, 2018 – 115 stroke hospitals 91% of MN residents live within 30 minutes of a designated stroke center! Minnesota Department of Health

Transient Ischemic Attacks (TIAs) “Warning strokes” that can happen before a major stroke ~5 million Americans will experience a TIA Almost 10 times more likely to have a stroke Get a good history, rule out possible mimics Seizure Hypo/hyperglycemia Migraine Conversion disorder/reaction Hypertensive encephalopathy Drug toxicity Benjamin EJ et al. Circulation 2018;137:e67-e492.

TIA Workup: Inpatient vs Outpatient ABCD2 score (0-7) Age ≥ 60 years (1) Blood pressure (1) Systolic ≥ 140 mmHg Diastolic ≥ 90 mmHg Clinical features Unilateral weakness (2) Speech impairment without weakness (1) Duration ≥ 60 minutes (2) 10-59 minutes (1) Presence of diabetes mellitus (1) Johnston SC et al. Lancet 2007;369:283-292.

TIA Workup: Inpatient vs Outpatient ABCD2 score 2-Day risk (%) 7-Day risk (%) 90-Day risk (%) 0-3 1.0 1.2 3.1 4-5 4.1 5.9 9.8 ≥6 8.1 11.7 17.8 Johnston SC et al. Lancet 2007;369:283-292.

But first…

Acute Ischemic Stroke Treatment Options IV alteplase is recommended for selected patients who may be treated within 3 hours of onset of ischemic stroke (Class I Recommendation, Level of Evidence A) IV alteplase should be administered to eligible patients who can be treated in the time period of 3 to 4.5 hours after stroke (Class I Recommendation, Level of Evidence B) Patients should receive mechanical thrombectomy …within 6 hours of symptom onset (Class I Recommendation, Level of Evidence A) if eligible If eligible patients can receive mechanical thrombectomy Between 6 and 16 hours of symptom onset (Class I Recommendation, Level of Evidence A) Between 16 and 24 hours of symptom onset (Class I Recommendation, Level of Evidence B-R) Powers WJ et al. Stroke 2018;49:e46-e110

Acute Ischemic Stroke Treatment Options Because time from onset of symptoms to treatment has such a powerful impact on outcomes, treatment with IV alteplase should not be delayed to monitor for further improvement (Class III Recommendation, Level of Evidence C-EO) Powers WJ et al. Stroke 2018;49:e46-e110

Rural-Urban Inequity in IV alteplase From 2012-2017: 103 rural hospitals IV alteplase use increased from 12.9% to 15.9% of all stroke patients (p=0.0013) Gonzales S et al. Neurology 2017;88:441-448 Tsai AW et al. Stroke. 2018;49:AWP276

Work Up for the Stroke/TIA Patient

Cranial Imaging Computed tomography (CT) head Hemorrhage? Can be negative in the first few hours with increased sensitivity several hours later Early CT signs of ischemia confers worse prognosis Wardlaw JM et al. Radiology 2005;235:444-453.

Cranial Imaging Magnetic Resonance Imaging (MRI) More sensitive that CT Not as generalizable Do you need to transfer the patient?

Vessel Imaging Carotid Dopplers MRA/CTA Digital subtracted angiography Extra- and intracranial vasculature Digital subtracted angiography Gold standard

Cardiac Imaging Transthoracic Echocardiography “Widely available” Transesophageal Echocardiography Aortic arch atherosclerosis Patent foramen ovale and/or atrial septum aneurysm Intracardiac tumor Endocarditis Left atrial appendage thrombus 3% Christiansen ME et al. Neurologist 2018;23:30-33.

Immediate Anticoagulation Arterial occlusion – why not? When compared to aspirin or placebo No evidence in superior prevention of stroke within 14 days No significant difference in long-term outcome or independence High risk of intracranial bleeding within 7 days No variation across etiologies of stroke Not recommended for treatment of patients with AIS (Class III Recommendation, Level of Evidence A) Berge E et al. Lancet 2000;355:1205-1210. TOAST Investigators. JAMA 1998;274:702-710. Bath PM et al. Lancet 2001;358:702-710. Powers WJ et al. Stroke 2018;49:e46-e110

Antiplatelets for Noncardioembolic Strokes FDA approval for secondary prevention of stroke/TIA Aspirin (Class I; Level of Evidence A) Aspirin/dipyridamole (Class I; Level of Evidence B) Clopidogrel (Class IIa; Level of Evidence B) Kernan et al. Stroke 2014;45:2160-2236.

Dual Antiplatelet (aspirin/clopidogrel) Not beneficial in secondary risk prevention for non-acute events (if initiated within 3 or 6 months of stroke) May be of benefit if started acutely (within 24 hours) for severe TIA or minor stroke 21 days within Chinese population 90 days in a more generalizable population Intracranial severe stenosis (70-99%) 3 month therapy Aggressive medical management No net benefit when used > 1 year Diener HC et al. Lancet 2004;364:331-337. Cote R et al. Neurology 2014;82:382-389. Wang Y et al. N Engl J Med 2013;369:11-19. Chimowitz M et al. N Engl J Med 2011;365:993-1003. Zaidat OO et al. JAMA 2015;313:1240-1248. Lee M et al. Ann Intern Med 2013;159:463-470. Johnston SC et al. N Engl J Med 2018;379:215-225.

Long-term Anticoagulation Warfarin Atrial fibrillation (Class I; Level of Evidence A) Mechanical aortic or mitral valve (Class I; Level of Evidence B/C) Intracardiac thrombus (Class I; Level of Evidence C) Left ventricular assist device (Class IIa; Level of Evidence C) Cardiomyopathy with ejection fraction < 35% (Class IIb; Level of Evidence B) Rheumatic mitral valve disease (Class IIb; Level of Evidence C) Kernan et al. Stroke 2014;45:2160-2236.

Direct Oral Anticoagulants Nonvalvular atrial fibrillation Apixaban Rivaroxaban Dabigatran Edoxaban

Outpatient Arrhythmia Monitoring Current duration of outpatient monitoring is undetermined At least 24 hours upon admission for stroke External monitors 7-, 14-, 28-, and 30-day monitors Insertable monitors Up to 3 years Jauch E et al. Stroke 2013;44:870-947.

Proportion of Cardiovascular Disease Risks by Age Asberg S et al. Stroke 2014;41:1338-1342.

Lipid Management High dose atorvastatin Prior stroke or TIA Reduction in recurrent stroke completed with placebo SPARCL Investigators. N Engl J Med 2006;355:549-559.

Blood Pressure Control

“Basic Work Up” CT head Carotid Dopplers TTE Lipids Hemoglobin A1c Screening labs (PT/INR) Electrocardiogram

Conclusions Not all patients need to be transferred to a “larger” hospital for stroke/TIA work up Confer with a neurologist when you can Strokes are not all the same Patients presenting with acute stroke symptoms to the emergency department should still be considered for acute stroke treatments